Coya Therapeutics, Inc. SEC filings COYA
Coya Therapeutics, Inc. has 230 filings in SEC EDGAR's recent list, going back to Jan 5, 2021. Its latest annual report, Form ARS, was filed on May 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jul 27, 2026 | — |
| 4 | Insider transaction | Apr 9, 2026 | Apr 9, 2026 |
| 3 | Initial insider ownership | Apr 9, 2026 | Apr 1, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 12, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 30, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 28, 2026 | — |
| 4 | Insider transaction | Jan 26, 2026 | Jan 22, 2026 |
| 4 | Insider transaction | Jan 26, 2026 | Jan 22, 2026 |
| 4 | Insider transaction | Jan 26, 2026 | Jan 22, 2026 |
| 4 | Insider transaction | Jan 26, 2026 | Jan 22, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Aug 19, 2025 | Aug 18, 2025 |
| 4 | Insider transaction | Feb 25, 2025 | Feb 25, 2025 |
| 4 | Insider transaction | Feb 25, 2025 | Feb 25, 2025 |
| 4 | Insider transaction | Feb 25, 2025 | Feb 25, 2025 |
| 4 | Insider transaction | Feb 25, 2025 | Feb 25, 2025 |
| 4 | Insider transaction | Feb 25, 2025 | Feb 25, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 10, 2025 | — |
| 4 | Insider transaction | Jan 13, 2025 | Jan 9, 2025 |
| 4 | Insider transaction | Jan 13, 2025 | Jan 9, 2025 |
| 4 | Insider transaction | Jan 13, 2025 | Jan 9, 2025 |
| 4 | Insider transaction | Jan 13, 2025 | Jan 9, 2025 |
| 4 | Insider transaction | Jan 3, 2025 | Jan 1, 2025 |
| 4 | Insider transaction | Jan 3, 2025 | Jan 1, 2025 |
| 4 | Insider transaction | Jan 3, 2025 | Jan 1, 2025 |
| 4 | Insider transaction | Jan 3, 2025 | Jan 1, 2025 |
| 4 | Insider transaction | Jan 3, 2025 | Jan 1, 2025 |
| 4 | Insider transaction | Nov 14, 2024 | Nov 14, 2024 |
| 4 | Insider transaction | Nov 13, 2024 | Nov 13, 2024 |
| 4 | Insider transaction | Nov 12, 2024 | Nov 11, 2024 |
| 4 | Insider transaction | Nov 12, 2024 | Nov 11, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 12, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 4, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 4, 2024 | — |
| 3 | Initial insider ownership | Aug 20, 2024 | Aug 19, 2024 |
| 4 | Insider transaction | Jun 5, 2024 | Jun 3, 2024 |
| 4 | Insider transaction | Jun 5, 2024 | Jun 3, 2024 |
| 4 | Insider transaction | Jun 5, 2024 | Jun 3, 2024 |
| 4 | Insider transaction | Mar 5, 2024 | Aug 22, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 7, 2024 | — |
| 4 | Insider transaction | Feb 2, 2024 | Jan 31, 2024 |
| 4 | Insider transaction | Feb 2, 2024 | Feb 2, 2024 |
| 4 | Insider transaction | Feb 2, 2024 | Jan 31, 2024 |
| 4 | Insider transaction | Jan 19, 2024 | Jan 1, 2024 |
| 4 | Insider transaction | Jan 19, 2024 | Jan 1, 2024 |
| 4 | Insider transaction | Jan 19, 2024 | Jan 1, 2024 |
| 4 | Insider transaction | Jan 19, 2024 | Jan 1, 2024 |
| 4 | Insider transaction | Jan 19, 2024 | Jan 1, 2024 |
| 4 | Insider transaction | Jan 4, 2024 | Jan 2, 2024 |
| 3 | Initial insider ownership | Dec 29, 2023 | Dec 19, 2023 |
| SC 13G | Ownership over 5% (passive) | Dec 12, 2023 | — |
| 4 | Insider transaction | Aug 21, 2023 | Aug 18, 2023 |
| 3 | Initial insider ownership | Aug 21, 2023 | Aug 18, 2023 |
| 4 | Insider transaction | Jul 19, 2023 | Jul 17, 2023 |
| 3 | Initial insider ownership | Jul 19, 2023 | Jul 17, 2023 |
| 4 | Insider transaction | Mar 1, 2023 | Feb 27, 2023 |
| 4 | Insider transaction | Mar 1, 2023 | Feb 27, 2023 |
| 4 | Insider transaction | Mar 1, 2023 | Feb 27, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2023 | — |
| 4/A | Filing | Jan 17, 2023 | Jan 3, 2023 |
| SC 13G | Ownership over 5% (passive) | Jan 5, 2023 | — |
| 4 | Insider transaction | Jan 4, 2023 | Jan 3, 2023 |
| 4 | Insider transaction | Jan 4, 2023 | Jan 3, 2022 |
| 4 | Insider transaction | Jan 4, 2023 | Jan 3, 2023 |
| 4 | Insider transaction | Jan 4, 2023 | Jan 3, 2023 |
| 4 | Insider transaction | Jan 4, 2023 | Jan 3, 2023 |
| 4 | Insider transaction | Jan 4, 2023 | Jan 3, 2023 |
| 4 | Insider transaction | Jan 4, 2023 | Jan 3, 2023 |
| 3 | Initial insider ownership | Dec 28, 2022 | Dec 28, 2022 |
| 3 | Initial insider ownership | Dec 28, 2022 | Dec 28, 2022 |
| 3 | Initial insider ownership | Dec 28, 2022 | Dec 28, 2022 |
| 3 | Initial insider ownership | Dec 28, 2022 | Dec 28, 2022 |
| 3 | Initial insider ownership | Dec 28, 2022 | Dec 28, 2022 |
| 3 | Initial insider ownership | Dec 28, 2022 | Dec 28, 2022 |
| 3 | Initial insider ownership | Dec 28, 2022 | Dec 28, 2022 |
| 3 | Initial insider ownership | Dec 28, 2022 | Dec 28, 2022 |
Showing 83 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COYA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1835022
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.